^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    JNJ-9530

    i
    Other names: JNJ 9530, CAR-066, CCAR066, JNJ90009530, JNJ9530, JNJ-9530, JNJ-90009530, C-CAR066 , CD20-directed CAR T-cell, Autologous 2nd generation CD20-directed CAR-T cells, CAR066, CBM.CD20 CAR-T, CBM-CD20, CAR 066, C CAR066, JNJ 90009530
    Associations

    News

    Trials
    Company:
    AbelZeta Pharma, J&J
    Drug class:
    CD20-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    3ms
    A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL) (clinicaltrials.gov)
    P1, N=20, Recruiting, Janssen Research & Development, LLC | N=92 --> 20
    Enrollment change • CAR T-Cell Therapy
    |
    JNJ-9530
    1year
    A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL) (clinicaltrials.gov)
    P1, N=92, Recruiting, Janssen Research & Development, LLC | Not yet recruiting --> Recruiting | Phase classification: P1b --> P1 | N=52 --> 92 | Trial completion date: Nov 2026 --> May 2027 | Trial primary completion date: May 2026 --> Apr 2027
    Enrollment open • Phase classification • Enrollment change • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    JNJ-9530
    1year
    Two-Year Follow-up Results of C-CAR066, a Novel Anti-CD20 Chimeric Antigen Receptor Cell Therapy (CAR-T) in Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Patients after Failure of CD19 CAR-T Therapy (ASH 2023)
    This pt recovered after receiving corticosteroids and tocilizumab. Longer term follow-up demonstrated that C-CAR066 can produce a deep and durable response with a favorable safety profile in pts with r/r LBCL who failed prior CD19 CAR-T therapy.
    Clinical
    |
    CD79B (CD79b Molecule) • CD22 (CD22 Molecule)
    |
    Actemra IV (tocilizumab) • JNJ-9530
    over1year
    A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy (clinicaltrials.gov)
    P1, N=7, Completed, Institute of Hematology & Blood Diseases Hospital | Unknown status --> Completed | N=10 --> 7 | Trial completion date: Dec 2021 --> Feb 2023 | Trial primary completion date: Aug 2021 --> Feb 2023
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    JNJ-9530
    over1year
    A Study of C-CAR066 in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T Therapy (clinicaltrials.gov)
    P1, N=14, Completed, Shanghai Tongji Hospital, Tongji University School of Medicine | Unknown status --> Completed
    Trial completion
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    JNJ-9530
    over1year
    A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL) (clinicaltrials.gov)
    P1, N=52, Not yet recruiting, Janssen Research & Development, LLC | N=15 --> 52 | Trial completion date: Oct 2025 --> May 2026 | Initiation date: Jul 2023 --> Oct 2023 | Trial primary completion date: Jul 2025 --> May 2026
    Enrollment change • Trial completion date • Trial initiation date • Trial primary completion date • CAR T-Cell Therapy
    |
    CD20 positive
    |
    JNJ-9530
    over1year
    C-CAR066 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL) (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, Cellular Biomedicine Group, Inc.
    New P1 trial • CAR T-Cell Therapy
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    JNJ-9530
    over3years
    [VIRTUAL] Safety and efficacy of a novel anti-CD20 chimeric antigen receptor (CAR)-T cell therapy in relapsed/refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL) patients after failing CD19 CAR-T therapy. (ASCO 2021)
    Preclinical studies suggest that C-CAR066 has superior anti-tumor activity compared to CAR-Ts derived from scFVs of Leu16, Rituximab and Obinutuzumab and anti-CD19 BBZ CAR with FMC63...A 3-day cyclophosphamide plus fludarabine regimen was followed by a single infusion of C-CAR066...One patient had grade 4 CRS and recovered after treatment with tocilizumab and corticosteroids... C-CAR066 has shown a favorable safety profile and promising efficacy in patients with r/r B-NHL following failure of CD19 CAR-T therapy . These results show that C-CAR066 has a different mechanism of action compared to anti-CD-19 CAR-T therapy and could provide a solution to address the unmet medical need in B-NHL patients that have failed anti-CD19 CAR-T therapy.
    Clinical
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule)
    |
    Rituxan (rituximab) • Gazyva (obinutuzumab) • fludarabine IV • Actemra IV (tocilizumab) • JNJ-9530